Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis

Modern Pathology

Volumn 19, Issue 1, 2006, Pages 25-33

  Kanungo, Anuradha ^a   Medeiros, L Jeffrey ^a   Abruzzo, Lynne V ^a   Lin, Pei ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

8q24; Burkitt lymphoma; c MYC; t(14; 18)

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; RITUXIMAB;

ADULT; AGED; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE TRANSLOCATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA; LYMPH NODE; LYMPHATIC SYSTEM TUMOR; MALE; MORPHOLOGY; MYELOMA; ONCOGENE C MYC; PLASMABLASTIC MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR BIOPSY;

ADULT; AGED; ANTIGENS, CD20; ANTIGENS, CD5; BURKITT LYMPHOMA; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; KI-67 ANTIGEN; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC;

EID: 32844456419     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800500     Document Type: Article

References (25)

1. Diebold J, Jaffe ES, Raphael M, et al. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H and Vardiman JW (eds). World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 181-184.
2. Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med 2003;127:1148-1160.
3. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18:3707-3721.
4. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-5610.
5. Au WY, Horsman DE, Gascoyne RD, et al. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymph 2004;45:519-528.
6. Voorhees PM, Carder KA, Smith SV, et al. Follicular lymphoma with a Burkitt translocation - predictor of an aggressive clinical course: a case report and review of the literature. Arch Pathol Lab Med 2004;128:210-213.
7. Mukhopadhyay S, Readling J, Cotter PD, et al. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Hum Pathol 2005;36:571-575.
8. Merchant S, Schlette E, Sanger W, et al. Mature B-cell leukemia with more than 55% prolymphocytes: report of 2 cases with Burkitt lymphoma-type chromosomal translocations involving c-MYC. Arch Pathol Lab Med 2003;127:305-309.
9. Hao S, Sanger W, Onciu M, et al. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol 2002;15:1266-1272.
10. Lin P, Bueso-Ramos C, Wilson CS, et al. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients. Am J Surg Pathol 2003;27:1104-1113.
11. Mitelman F (ed). An International System for Human Cytogenetic Nomenclature. Karger, ISCN: Basel, Switzerland, 1995.
12. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999;17:1558-1567.
13. Thangavelu M, Olopade O, Beckman E, et al. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer 1990;2:147-158.
14. Dunphy CH, van Deventer HW, Carder KJ, et al. Mature B-cell acute lymphoblastic leukemia with associated translocations (14;18)(q32;q21) and (8;9)(q24;p13). A Burkitt variant? Arch Pathol Lab Med 2003;127:610-613.
15. Gluck WL, Bigner SH, Borowitz MJ, et al. Acute lymphoblastic leukemia of Burkitt's type (L3 ALL) with 8;22 and 14;18 translocations and absent surface immunoglobulins. Am J Clin Pathol 1986;85:636-640.
16. Karsan A, Gascoyne RD, Coupland RW, et al. Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymph 1993;10:433-441.
17. Brito-Babapulle V, Crawford A, Khokhar T, et al. Translocations t(14;18) and t(8;14) with rearranged bcl-2 and c-MYC in a case presenting as B-ALL (L3). Leukemia 1991;5:83-87.
18. Mufti GJ, Hamblin TJ, Oscier DG, et al. Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. Blood 1983;62:1142-1146.
19. Geisler C, Philip P, Plesner T, et al. Simultaneous presence of translocations t(14;18) and t(2;8) in a case of chronic lymphocytic leukemia. Cancer Genet Cytogenet 1986;22:35-44.
20. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-MYC oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-308621.
21. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005;18:806-815.
22. Marin MC, Hsu B, Stephens LC, et al. The functional basis of c-MYC and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res 1995;217:240-247.
23. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349:254-256.
24. Gauwerky CE, Hoxie J, Nowell PC, et al. Pre B-cell leukemia with a t(8;14) and a t(14;18) translocation is preceded by follicular lymphoma. Oncogene 1998;2:431-435.
25. Martin-Subero JI, Odero MD, Hernandez R, et al. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes Cancer 2005;43:414-423.